Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Jennifer Munday, Mallik Greene, Eunice Chang, Ann Hartry, Tingjian Yan & Michael S. Broder. (2019) Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Current Medical Research and Opinion 35:7, pages 1231-1239.
Read now
Read now
Antoine C. El Khoury, Dominic Pilon, Laura Morrison, Nina Shak, Maude Vermette-Laforme, Tony B. Amos, Edward Kim & Patrick Lefebvre. (2019) The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. Current Medical Research and Opinion 35:3, pages 395-405.
Read now
Read now
Eduard Parellada, Miquel Bioque, Manuel Serrano, Berta Herrera & Marta García Dorado. (2018) An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study). International Journal of Psychiatry in Clinical Practice 22:3, pages 191-199.
Read now
Read now
Thomas R. Einarson, Hanna Pudas, Pushpendra Goswami, Kristel van Impe & Basil G. Bereza. (2016) Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. Journal of Medical Economics 19:2, pages 121-130.
Read now
Read now
John M. Kane, Cathy Zhao, Brian R. Johnson, Ross A. Baker, Anna Eramo, Robert D. McQuade, Anna R. Duca, Raymond Sanchez & Timothy Peters-Strickland. (2015) Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of Medical Economics 18:2, pages 145-154.
Read now
Read now
Gabriel Kaplan, Julio Casoy & Jacqueline Zummo. (2013) Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Preference and Adherence 7, pages 1171-1180.
Read now
Read now
John M. Kane, Raymond Sanchez, Joan Zhao, Anna R. Duca, Brian R. Johnson, Robert D. McQuade, Anna Eramo, Ross A. Baker & Timothy Peters-Strickland. (2013) Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. Journal of Medical Economics 16:7, pages 917-925.
Read now
Read now
Articles from other publishers (13)
Yifei Liu, Mark E. Patterson, Suman Sahil & Steven C. Stoner. (2023) Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations. Frontiers in Pharmacology 14.
Crossref
Crossref
Alex Z. Fu, Jacqueline A. Pesa, Susan Lakey & Carmela Benson. (2022) Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia. BMC Psychiatry 22:1.
Crossref
Crossref
Tiffany Cristarella, Genaro Castillon, Jean‐François Nepveu & Yola Moride. (2022) Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta‐analysis of observational studies. Pharmacology Research & Perspectives 10:1.
Crossref
Crossref
Dee Lin, Philippe Thompson-Leduc, Isabelle Ghelerter, Ha Nguyen, Marie-Hélène Lafeuille, Carmela Benson, Panagiotis Mavros & Patrick Lefebvre. (2021) Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs 35:5, pages 469-481.
Crossref
Crossref
Mei‐Chih Meg Tseng, Chao‐Ying Tu & Yuan‐Ting Chang. (2020) Healthcare use and costs of adults with anorexia nervosa and bulimia nervosa in Taiwan. International Journal of Eating Disorders 54:1, pages 69-80.
Crossref
Crossref
Maria Paz Garcia-Portilla, Pierre-Michel Llorca, Giuseppe Maina, Vasilis P. Bozikas, Halise Devrimci-Ozguven, Sung-Wan Kim, Paul Bergmans, Irina Usankova & Katalin Pungor. (2020) Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. Therapeutic Advances in Psychopharmacology 10, pages 204512532092634.
Crossref
Crossref
Mark Pennington & Paul McCrone. (2017) The Cost of Relapse in Schizophrenia. PharmacoEconomics 35:9, pages 921-936.
Crossref
Crossref
Philippe D. Vincent, Marie-France Demers, Venessa Doyon-Kemp, Jos?e Duchesneau, Alex Halme & Violaine Masson. (2017) One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada. Schizophrenia Research 185, pages 96-100.
Crossref
Crossref
Flore Decuypere, Jan Sermon, Paul Geerts, Tom R. Denee, Cedric De Vos, Bart Malfait, Mark Lamotte & Cornelis L. Mulder. (2017) Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study. PLOS ONE 12:6, pages e0179049.
Crossref
Crossref
Georgia L. Stevens, Gail Dawson & Jacqueline Zummo. (2015) Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia. Early Intervention in Psychiatry 10:5, pages 365-377.
Crossref
Crossref
Ivana Simić-Medojević & Marija Burgić-Radmanović. (2015) Quality of life of schizophrenic patients with or without depot neuroleptics. Scripta Medica 46:1, pages 60-65.
Crossref
Crossref
Matt Shirley & Caroline M. Perry. (2014) Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia. Drugs 74:10, pages 1097-1110.
Crossref
Crossref
Daniel C. Javitt. (2014) Current and Emergent Treatments for Symptoms and Neurocognitive Impairment in Schizophrenia. Current Treatment Options in Psychiatry 1:2, pages 107-120.
Crossref
Crossref